A trial supports the use of the calcineurin-inhibitor tacrolimus as a targeted treatment for uremic pruritus and introduces IL-13 inhibition as a viable mechanism to address cytokine-mediated itch.
Opioid-based therapies and gamma-aminobutyric acid analogues have potential for treating uremic pruritus, according to separate meta-analyses. The kappa opioid receptor (KOR) agonists difelikefalin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results